for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Checkpoint Therapeutics Inc

CKPT.O

Latest Trade

2.81USD

Change

0.07(+2.55%)

Volume

732,791

Today's Range

2.68

 - 

2.85

52 Week Range

1.05

 - 

4.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.74
Open
2.72
Volume
732,791
3M AVG Volume
26.34
Today's High
2.85
Today's Low
2.68
52 Week High
4.50
52 Week Low
1.05
Shares Out (MIL)
60.04
Market Cap (MIL)
198.11
Forward P/E
-7.54
Dividend (Yield %)
--

Latest Developments

More

CVI Investments Inc Reports 5.5% Passive Stake In Checkpoint Therapeutics

Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering

Checkpoint Announces Positive Interim Results From Registration-Enabling Trial Of Cosibelimab

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.

Industry

Biotechnology & Drugs

Contact Info

2 Gansevoort St Fl 9

NEW YORK, NY

10014-1667

United States

+1.212.5544366

http://www.checkpointtx.com

Executive Leadership

Michael S. Weiss

Chairman of the Board

James F. Oliviero

President, Chief Executive Officer, Director

William Garrett Gray

Vice President - Finance and Accounting, Principal Financial Officer, Corporate Secretary

Lindsay A. Rosenwald

Director

Christian Bechon

Independent Director

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020(E)

0.0K
EPS (USD)

2020(E)

-0.340
Price To Earnings (TTM)
--
Price To Sales (TTM)
150.19
Price To Book (MRQ)
10.61
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-197.97
Return on Equity (TTM)
-115.85

Latest News

Latest News

BRIEF-Checkpoint Therapeutics Reports Q1 Loss Per Share $0.06

* CHECKPOINT THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

BRIEF-Checkpoint Announces Issuance Of U.S. Composition Of Matter Patent For Anti-PD-L1 Antibody Cosibelimab

* CHECKPOINT THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. COMPOSITION OF MATTER PATENT FOR ANTI-PD-L1 ANTIBODY COSIBELIMAB

BRIEF-Checkpoint Therapeutics Reports Full-Year Results

* CHECKPOINT THERAPEUTICS REPORTS FULL-YEAR 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS Source text for Eikon: Further company coverage:

BRIEF-Checkpoint Therapeutics files for mixed shelf offering of up to $100 mln - SEC filing

* Checkpoint Therapeutics Inc - files for mixed shelf offering of up to $100 million - SEC filing Source text: (http://bit.ly/2zKSDGZ) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up